Baricitinib (INCB28050,LY3009104)

inquiry

Cat No.

CEI-0198

Description

Baricitinib (INCB28050, LY3009104) can inhibit JAK1 and JAK2 with IC50 of 5.9 nM and 5.7 nM.

Alias

INCB 28050

CAS_No

1187594-09-7

Molecular Weight

371.41688

Purity

>99%

Storage

2 years at -20centigrade Powder

Synonyms

INCB 28050

Targets

JAK1, JAK2

Molecular Formula

C16H17N7O2S

Chemical Name

3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-

Solubility

DMSO 74 mg/mL Water

In vitro

As an ATP competitive kinase inhibitor, INCB028050 (Baricitinib, LY3009104) was a potent inhibitor of JAK1 and JAK2 with IC50 values of 5.9 and 5.7 nM, respectively. INCB0-28050 (Baricitinib, LY3009104), a potent and selective inhibitor of JAK1/2, is shown to inhibit signaling from pathogenic cytokines such as IL-6 and IL-23. Inhibition of JAK signaling prevents the production of chemokines and cytokines associated with uncontrolled RA. In cell-based assays, INCB028050 proved to be a potent inhibitor of JAK signaling and function. In PBMCs, INCB028050 inhibited IL-6-stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) and subsequent production of the chemokine MCP-1 with IC50 values of 44 nM and 40 nM, respectively. In isolated naive T-cells, INCB028050 also inhibited pSTAT3 stimulated by IL-23 (IC 50 = 20 nM).

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry